Is cancer gene therapy an empty suit?

The Lancet Oncology

Volumn 14, Issue 11, 2013, Pages

  Brenner, Malcolm K ^a,b   Gottschalk, Stephen ^a,b   Leen, Ann M ^a,b   Vera, Juan F ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; DENDRITIC CELL VACCINE; FLUOROURACIL; LONTUCIREV; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SIPULEUCEL T; THYMIDINE KINASE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; DNA MODIFICATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HERPES VIRUS; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; LENTIVIRINAE; MELANOMA; MYELOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RETROVIRUS; REVIEW; T LYMPHOCYTE; TRANSGENE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

EID: 84884695554     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70173-6     Document Type: Review

References (73)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
2. Gottschalk S, Rooney CM, Brenner MK Cell and gene therapy. Principles and Practice of Pediatric Oncology 2011, 426-445. Lippicott Williams & Wilkins, Philadelphia, PA, USA. P.A. Pizzo, D.G. Poplack (Eds.).
3. Yates LR, Campbell PJ Evolution of the cancer genome. Nat Rev Genet 2012, 13:795-806.
4. Swanton C Intratumor heterogeneity: evolution through space and time. Cancer Res 2012, 72:4875-4882.
5. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011, 365:2357-2365.
6. Niculescu-Duvaz I, Springer CJ Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005, 30:71-88.
7. Westphal M, Ylä-Herttuala S, Martin J, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol (in press).
8. Chiocca EA Oncolytic viruses. Nat Rev Cancer 2002, 2:938-950.
9. Lin E, Nemunaitis J Oncolytic viral therapies. Cancer Gene Ther 2004, 11:643-664.
10. Liu TC, Galanis E, Kirn D Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007, 4:101-117.
11. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997, 3:639-645.
12. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6:611-623.
13. Patel MR, Kratzke RA Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 2013, 161:355-364.
14. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-885.
15. Yu W, Fang H Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007, 7:141-148.
16. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013, 19:329-336.
17. Tandle A, Blazer DG, Libutti SK Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2004, 2:22.
18. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004, 64:1781-1787.
19. Lin X, Huang H, Li S, et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007, 6:648-653.
20. Hanania EG, Giles RE, Kavanagh J, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996, 93:15346-15351.
21. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998, 16:165-172.
22. Adair JE, Beard BC, Trobridge GD, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 2012, 4:133ra57.
23. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004, 113:1515-1525.
24. Ridgway D The first 1000 dendritic cell vaccinees. Cancer Invest 2003, 21:873-886.
25. Nencioni A, Grünebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008, 65:191-199.
26. Goldman B, DeFrancesco L The cancer vaccine roller coaster. Nat Biotechnol 2009, 27:129-139.
27. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
28. Stevenson FK, Mander A, Chudley L, Ottensmeier CH DNA fusion vaccines enter the clinic. Cancer Immunol Immunother 2011, 60:1147-1151.
29. Liu MA DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239:62-84.
30. Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002, 62:5845-5852.
31. Tagawa ST, Lee P, Snively J, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 2003, 98:144-154.
32. Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002, 8:2782-2787.
33. Boczkowski D, Nair SK, Synder D, Gilboa E Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184:465-472.
34. Radford KJ, Jackson AM, Wang JH, Vassaux G, Lemoine NR Recombinant E coli efficiently delivers antigen and maturation signals to human dendritic cells: presentation of MART1 to CD8+ T cells. Int J Cancer 2003, 105:811-819.
35. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000, 86:385-392.
36. Gottschalk S, Edwards OL, Sili U, et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003, 101:1905-1912.
37. Wei Y, Sticca RP, Holmes LM, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 2006, 28:585-593.
38. Jinushi M, Hodi FS, Dranoff G Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008, 222:287-298.
39. Biagi E, Rousseau R, Yvon E, et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 2005, 11:6916-6923.
40. Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 2004, 172:7200-7205.
41. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996, 2:1090-1095.
42. Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002, 9:9-15.
43. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
44. Li LP, Lampert JC, Chen X, et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 2010, 16:1029-1034.
45. Leisegang M, Wilde S, Spranger S, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 2010, 120:3869-3877.
46. Stauss HJ, Cesco-Gaspere M, Thomas S, et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther 2007, 15:1744-1750.
47. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
48. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
49. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011, 19:620-626.
50. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013, 36:133-151.
51. Maus MV, Linette GP, Stadtmauer EA, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced TCR-engineered T cells against HLA-A1 restricted MAGE-A3 antigen. Mol Ther 2013, 21:S24. (abstr).
52. Porter DL, Levine BL, Kalos M, Bagg A, June CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
53. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
54. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
55. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
56. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822-1826.
57. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T Cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
58. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
59. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
60. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
61. Heslop HE Safer CARS. Mol Ther 2010, 18:661-662.
62. Büning H, Uckert W, Cichutek K, Hawkins RE, Abken H Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther 2010, 21:1039-1042.
63. Peinert S, Kershaw MH, Prince HM Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Immunotherapy 2009, 1:905-912.
64. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006, 24:e20-e22.
65. Bollard CM, Rössig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002, 99:3179-3187.
66. Bollard CM, Dotti G, Gottschalk S, et al. Administration of TGF-beta resistant tumor-specific CTL to patienst with EBV-associated HL and NHL. Mol Ther 2012, 20:S22.
67. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
68. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A Gene therapy for primary immunodeficiencies: part 1. Curr Opin Immunol 2012, 24:580-584.
69. Ciceri F, Bonini C, Gallo-Stampino C, Bordignon C Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy 2005, 7:144-149.
70. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007, 109:4698-4707.
71. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007, 109:4708-4715.
72. Straathof KC, Pulè MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
73. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.